LPCN Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Lipocine Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerLPCN

Market Cap19.1M

Cash RunwayRunway > 12 months

Next CatalystData Readout

Public Research Snapshot

Lipocine Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Oral testosterone undecanoate, LPCN 1021 in Male Hypogonadism (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Improving Maternal Mental Health	postpartum depression (PPD) treatment targeting Rapid Relief	n/a	n/a	Public pipeline row
Hypogonadism	n/a	n/a	n/a	Public pipeline row
Oral testosterone undecanoate, LPCN 1021	Male Hypogonadism	n/a	Phase 3	Public pipeline row
LPCN 1144 Formulation A	Nonalcoholic Steatohepatitis (NASH)	n/a	Phase 2	Public pipeline row
LPCN 1144	NASH - Nonalcoholic Steatohepatitis	n/a	Phase 2	Public pipeline row
LPCN 1154A	n/a	n/a	Phase 3	Public pipeline row
LPCN 1021	Hypogonadism, Male	n/a	Phase 3	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Data Readout	second quarter of 2026	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT02081300	Phase 3	COMPLETED	315	2015-05
NCT03242590	Phase 3	COMPLETED	95	2017-03
NCT03242408	Phase 3	COMPLETED	100	2017-05
NCT03868059	Phase 3	COMPLETED	138	2019-02-19
NCT04134091	Phase 2	COMPLETED	56	2021-06-24
NCT04685993	Phase 2	COMPLETED	25	2022-03-01
NCT06979544	Phase 3	COMPLETED	90	2026-01-16

Scientific Context

catalyst_type | Data Readout
catalyst_type | Data Readout
catalyst_type | Data Readout
catalyst_type | Data Readout
catalyst_type | Data Readout

Want the full LPCN research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.